GOALI: Aggregation of Protein Therapeutics in Aqueous Solutions

目标：蛋白质治疗药物在水溶液中的聚集

• 批准号: 0138595
• 负责人: Theodore Randolph
• 金额: $ 43.15万
• 依托单位: University of Colorado at Boulder
• 依托单位国家: 美国
• 项目类别: Continuing Grant
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-07-01 至 2006-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0138595&HistoricalAwards=false
• 关键词: GOALI; Aggregation; Protein; Therapeutics; Aqueous

Therapeutic proteins provide numerous unique treatments for human diseases (e.g., diabetes, and cancer). However, due to their delicate three-dimensional structures, proteins are very difficult to keep stable during the required 18-24 month shelf life of a pharmaceutical product. Furthermore, it is currently not possible to predict which solution conditions will result in sufficient stability. The Principal Investigators (PIs) propose to conduct fundamental studies of critical physical properties of proteins to develop methods for predicting optimal solution conditions for long-term stability. This multidisciplinary project combines efforts from Chemical Engineering and Pharmaceutical Sciences Departments at the University of Colorado with those of Amgen, an industrial partner. The PIs propose to determine the effects of critical solution conditions (pH, ionic strength and presence of stabilizing excipients) on rate and pathway for aggregation of several model proteins. Levels, and kinetics for formation and loss (where applicable) of soluble oligomeric species and insoluble precipitates will be measured, and structure of proteins in aggregates will be determined with infrared and derivative UV spectroscopies. To understand these effects, the PIs will determine the effects of pH, ionic strength and stabilizing excipients on protein structure and thermodynamic properties. Protein secondary and tertiary structures will be studied with circular dichroism, infrared, fluorescence and derivative-UV spectroscopies. The free energy of unfolding and hydrogen-deuterium exchange rates will be measured to test the hypothesis that increasing the thermodynamic stability of the native state and shifting the native state ensemble toward most compact species are important factors for inhibiting protein aggregation. The second osmotic virial coefficient will be measured by light scattering to assess the effects of solution conditions on the colloidal stability of the protein systems. High-pressure spectroscopic techniques will be used to complement these measurements. Finally, the effect of solution conditions on chemical stability (e.g., deamidation, oxidation and non-native disulfide formation) of the model proteins will be determined by the industrial collaborators at Amgen, and linkages between physical and chemical stability of the model proteins will be elucidated.

治疗性蛋白质为人类疾病（例如糖尿病和癌症）提供了许多独特的治疗方法。然而，由于其脆弱的三维结构，蛋白质在药品所需的 18-24 个月的保质期内很难保持稳定。此外，目前无法预测哪些解决方案条件将导致足够的稳定性。 首席研究员 (PI) 提议对蛋白质的关键物理特性进行基础研究，以开发预测长期稳定性最佳解决方案条件的方法。这个多学科项目结合了科罗拉多大学化学工程和制药科学系以及工业合作伙伴安进的努力。 PI 建议确定关键溶液条件（pH、离子强度和稳定赋形剂的存在）对几种模型蛋白聚集速率和途径的影响。将测量可溶性寡聚物和不溶性沉淀物的形成和损失（如适用）的水平和动力学，并通过红外和衍生的紫外光谱确定聚集体中蛋白质的结构。 为了了解这些影响，PI 将确定 pH 值、离子强度和稳定赋形剂对蛋白质结构和热力学性质的影响。蛋白质二级和三级结构将通过圆二色性、红外、荧光和衍生紫外光谱进行研究。将测量展开的自由能和氢-氘交换率，以检验以下假设：增加天然态的热力学稳定性和将天然态系综转向最紧凑的物种是抑制蛋白质聚集的重要因素。第二渗透维里系数将通过光散射测量，以评估溶液条件对蛋白质系统胶体稳定性的影响。高压光谱技术将用于补充这些测量。最后，溶液条件对模型蛋白化学稳定性（例如脱酰胺、氧化和非天然二硫键形成）的影响将由安进的工业合作者确定，模型蛋白的物理和化学稳定性之间的联系将由安进公司的工业合作者确定。阐明了。